Enhancing Cancer Treatment with Iron Chelators
Author Information
Author(s): A Curnowl, BW Mcilroy, MJ Postle-Hacon, JB Porter, AJ MacRobert, SG Bown
Primary Institution: National Medical Laser Centre, Institute of Surgical Studies, University College London Medical School
Hypothesis
Can hydroxypyridinone iron-chelating agents enhance the effectiveness of 5-aminolaevulinic acid-induced photodynamic therapy without increasing the ALA dose?
Conclusion
The simultaneous administration of the iron chelator CP94 with ALA significantly increases the area of necrosis produced by photodynamic therapy.
Supporting Evidence
- CP94 doubled the PPIX fluorescence in the colonic mucosa compared to ALA alone.
- The area of necrosis was three times larger with CP94 and ALA than with ALA alone.
- Fluorescence microscopy confirmed that PPIX was the predominant porphyrin present.
Takeaway
This study shows that adding a special iron medicine can make cancer treatment work better without needing to give more of the main medicine.
Methodology
Normal Wistar rats were treated with ALA and iron chelators, and fluorescence microscopy was used to measure the effects on tissue.
Limitations
The study was conducted on rats, and results may not directly translate to humans.
Participant Demographics
Normal, female, Wistar rats (120-200 g)
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website